LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

167 / 371 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. sept 2025, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. sept 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. sept 2025, 21:59 UTC

Tulu

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. sept 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. sept 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. sept 2025, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. sept 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. sept 2025, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. sept 2025, 21:00 UTC

Tulu

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. sept 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. sept 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. sept 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. sept 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. sept 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. sept 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. sept 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. sept 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. sept 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. sept 2025, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. sept 2025, 16:51 UTC

Tulu

Correct: Exor 1H Net Loss -EUR624M

17. sept 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. sept 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. sept 2025, 16:25 UTC

Tulu

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. sept 2025, 16:23 UTC

Tulu

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

167 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.